T231 and S262 contributed approximately 26% and 33%, respectively.[42] Hence, an efficient approach to treat AD should focus on targeting the initial stage of tau pathology, hyperphosphorylation‐induced aggregation. The gene discussed is MAPT; the disease is Alzheimer disease.